Barclays PLC Boosts Position in Rapport Therapeutics (NASDAQ:RAPP)

Barclays PLC raised its holdings in shares of Rapport Therapeutics (NASDAQ:RAPP) by 36.8% during the third quarter, HoldingsChannel reports. The institutional investor owned 12,863 shares of the company’s stock after acquiring an additional 3,463 shares during the quarter. Barclays PLC’s holdings in Rapport Therapeutics were worth $264,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. ARCH Venture Management LLC acquired a new position in shares of Rapport Therapeutics during the 2nd quarter valued at $86,730,000. Perceptive Advisors LLC acquired a new stake in Rapport Therapeutics in the 2nd quarter valued at $17,403,000. FMR LLC raised its position in Rapport Therapeutics by 10.1% in the third quarter. FMR LLC now owns 5,486,468 shares of the company’s stock valued at $112,363,000 after purchasing an additional 503,117 shares during the period. Logos Global Management LP acquired a new position in shares of Rapport Therapeutics during the second quarter worth about $4,859,000. Finally, Geode Capital Management LLC acquired a new position in shares of Rapport Therapeutics during the third quarter worth about $4,133,000.

Rapport Therapeutics Trading Up 1.4 %

RAPP stock opened at $12.69 on Tuesday. Rapport Therapeutics has a 1 year low of $12.09 and a 1 year high of $29.74. The stock has a 50-day simple moving average of $19.43 and a 200-day simple moving average of $21.20.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.